Scalper1 News
Genetic testing company Myriad Genetics (MYGN) hit a 52-week high on the stock market and got a couple of price-target increases Tuesday in the wake of its analyst day Monday. Myriad laid out a five-year plan to turn around its string of profit declines over the last five quarters. The business has been hit by two factors: the waning of publicity surrounding Angelina Jolie’s use of Myriad’s BRACAnalysis breast-cancer-gene test in 2013, and the Scalper1 News
Scalper1 News